The ACR Committee on Journal Publications announces the search for the position of editor in chief of Arthritis & Rheumatology. The official term of the next Arthritis & Rheumatology editorship is July 1, 2020–June 30, 2025; however, some of the duties of the new editor will begin during a transition period starting April 1, 2020….
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

Foundation Earns Coveted 4-Star Rating from Charity Navigator for 10th Consecutive Year
The Rheumatology Research Foundation’s strong financial health and commitment to accountability and transparency have earned yet another four-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the 10th consecutive time the Foundation has earned this top distinction. Only 1% of charities have ever received 10 consecutive four-star evaluations, indicating the Foundation outperforms…

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?
Results of a recent study in Arthritis & Rheumatology fail to clarify whether urate-lowering therapies may potentially reduce mortality risk in patients with gout.1 The study also underscores the fact that many physicians are not following the ACR guideline to help their patients achieve target serum urate levels. Partly because of this, it remains unclear…

Research Suggests Th17 Cells Have Microbiota-Dependent Role in RA
A growing body of research is elucidating the role of intestinal microbiota in several autoimmune diseases, including rheumatoid arthritis (RA). Research published in December 2018 Arthritis & Rheumatology increases our understanding of the “extent and nature of mucosal immune activation during preclinical arthritis.”1 The research objective, according to the report, was to “dissect intestinal mucosal immune…
Democrats Support Expanding Medicare, with Some Caveats that Could Matter to Voters
WASHINGTON/ST. GEORGE, S.C.—After launching his 2020 presidential bid last week, John Hickenlooper took a different stance on establishing a “Medicare-for-all” government health insurance program than many of his Democratic competitors. “I probably would oppose Medicare-for-all just because there are over 150 million people, Americans who have some form of private insurance through their business, and…
Rheumatoid Arthritis Risk Lower Among Smokers Who Quit
(Reuters Health)—Adults who quit smoking decades ago may have a lower risk of rheumatoid arthritis (RA) than people who gave up cigarettes more recently, a U.S. study suggests. Smoking has long been linked to an increased risk of RA, and quitting can reduce this risk. But the new study offers fresh evidence that years of…
Tainted Research Repeatedly Re-Used to Assess Drug Effectiveness
(Reuters Health)—A new study shows how fake news—specifically, information about scientific research that may be tainted by fraud—keeps getting spread through the medical literature, misleading doctors about the safety and effectiveness of the drugs they prescribe. At issue is the failure of medical journals to flag research that’s been identified by the U.S. Food and…
Practices Now Contributing to RheumPAC
Last year the ACR’s nonpartisan political action committee, RheumPAC, raised nearly $150,000 from individual contributors. Starting in 2019, the addition of the RheumPAC Advocacy Fund, where rheumatology practices and state societies can contribute corporate dollars, is expected to support RheumPAC fundraising efforts in an effort to surpass this dollar amount, giving rheumatology an even stronger…
Why Fellows Should Care about Advocacy
As a physician, I am an advocate. I am an advocate for my patients individually and collectively, and I am an advocate for my field: pediatric rheumatology. My own experiences as a patient drive me to integrate my patients’ perspectives into my medical decision making, and although my academic training has prepared me to best…
Duration & Treatment of Musculoskeletal Symptoms of Immunotherapy-Induced Arthritis
A new case series outlines the treatment and duration of symptoms of 10 patients experiencing the musculoskeletal manifestations of immune-related adverse events. Researchers found these symptoms may last for more than a year, but can generally be treated with low to moderate doses of corticosteroids…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 247
- Next Page »